A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT06147570 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonsmall Cell Lung Cancer

Interventions

DRUG: HS-10365 capsules

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.